8Other operating income and expenses
|
millions of CHF |
|
2022 |
|
2021 1) |
|
Gain from sale of property, plant and equipment |
|
7.5 |
|
1.0 |
|
Operating currency exchange gains, net |
|
– |
|
2.5 |
|
Other operating income |
|
9.1 |
|
10.6 |
|
Total other operating income |
|
16.6 |
|
14.1 |
|
|
|
|
|
|
|
Restructuring expenses |
|
–0.9 |
|
–1.8 |
|
Impairments on tangible and intangible assets |
|
–36.4 |
|
–0.3 |
|
Cost for mergers and acquisitions |
|
–0.4 |
|
–2.3 |
|
Loss from sale of property, plant and equipment |
|
–2.8 |
|
–0.0 |
|
Loss from deconsolidation of subsidiaries |
|
–6.7 |
|
–0.0 |
|
Operating currency exchange losses, net |
|
–9.9 |
|
– |
|
Total other operating expenses |
|
–57.2 |
|
–4.5 |
|
|
|
|
|
|
|
Total other operating income / (expenses), net |
|
–40.6 |
|
9.6 |
1) Comparative information has been re-presented due to discontinued operations (details are described in note 6).
Other operating income includes income from litigation cases, government grants and incentives, and recharges to third parties not qualifying as sales from customers. In 2021, other operating income included income from charges to the discontinued operation APS division (later renamed medmix) for corporate support functions and centrally procured indirect spend utilized by medmix of CHF 5.2 million.
The loss from deconsolidation of subsidiaries includes a loss of CHF 6.2 million resulting from the deconsolidation of two subsidiaries in Poland and a loss of CHF 0.6 million from the disposal of a subsidiary in Brazil (see note 4).
For the period ended June 30, 2022, the group recognized impairments of CHF 36.4 million (first half of 2021: CHF 0.3 million). Impairments of CHF 4.2 million (first half of 2021: CHF 0.3 million) were recorded based on performed impairment tests on production machines and facilities. Impairments of CHF 32.2 million on goodwill, other intangible assets, and property, plant and equipment were recorded in connection with the classification of the business in Russia as held for sale and the write-down to fair value less costs to sell (see note 7).
The functional allocation of the total restructuring expenses and impairments is estimated as follows: cost of goods sold CHF –24.8 million (first half of 2021: CHF –0.6 million), selling and distribution expenses CHF –6.7 million (first half of 2021: CHF –0.2 million), general and administrative expenses CHF –5.8 million (first half of 2021: CHF –1.3 million).